We are kicking off 2024 with five new R&D partnerships to further enable and accelerate the company’s commitment to transform the lives of patients world-wide.
It’s the smart combination of our cancer cell-directed and immuno-oncology approaches that may offer the greatest benefit for people living with cancer.
Boehringer Ingelheim and Mirati are teaming up in a clinical collaboration to evaluate the combination of the SOS1::pan-KRAS and the selective G12C inhibitor.
Today marks a significant step for Boehringer Ingelheim’s immuno-oncology pipeline by adding an innovative preclinical program with the acquisition of Nerio Therapeutics
We are developing complementary platforms (including, T Cell Engagers, oncolytic viruses, and cancer vaccines), which have the potential to turn cold tumors hot, extending the benefits of immunotherapy to more people.
Boehringer Ingelheim’s research approach in stromal biology may lead to new medicines that will change the face of cancer and give new hope to patients